Aberdeen Group plc Acquires 46,704 Shares of Insmed, Inc. $INSM

Key Points

• Aberdeen Group plc increased its stake in Insmed, Inc. by 16.1% during the first quarter, owning about 336,357 shares valued at $25.66 million.
• Insmed has received multiple buy ratings from analysts, with a consensus target price of $131.29, signifying strong market optimism.
• Despite a loss of $1.70 earnings per share in its recent quarter, Insmed saw an 18.9% revenue increase year-over-year, highlighting growth in sales.

Aberdeen Group plc boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 16.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 336,357 shares of the biopharmaceutical company's stock after acquiring an additional 46,704 shares during the period. Aberdeen Group plc owned approximately 0.18% of Insmed worth $25,661,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in INSM. Renaissance Technologies LLC bought a new stake in shares of Insmed in the fourth quarter worth $1,746,000. Mariner LLC raised its holdings in Insmed by 23.4% in the 4th quarter. Mariner LLC now owns 30,788 shares of the biopharmaceutical company's stock valued at $2,126,000 after acquiring an additional 5,844 shares during the period. Jump Financial LLC bought a new position in Insmed during the 4th quarter worth $230,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Insmed by 4.1% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 39,379 shares of the biopharmaceutical company's stock valued at $2,717,000 after acquiring an additional 1,568 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Insmed in the fourth quarter valued at about $2,167,000.

Insmed Trading Down 0.7%

NASDAQ:INSM traded down $0.8750 during mid-day trading on Friday, reaching $131.7250. 1,549,574 shares of the company's stock traded hands, compared to its average volume of 2,818,616. The company has a 50 day moving average price of $106.82 and a 200-day moving average price of $85.31. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $133.56. The firm has a market capitalization of $27.84 billion, a price-to-earnings ratio of -23.11 and a beta of 0.95. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same period in the prior year, the company posted ($1.94) EPS. The firm's revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Truist Financial boosted their target price on shares of Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Morgan Stanley increased their price target on Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a research note on Thursday. Wells Fargo & Company increased their price objective on shares of Insmed from $130.00 to $140.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 12th. UBS Group boosted their target price on shares of Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Finally, Bank of America raised their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Sixteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and a consensus price target of $132.57.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the transaction, the chief operating officer owned 105,637 shares in the company, valued at $13,477,168.46. This trade represents a 19.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO William Lewis sold 129,805 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $100.39, for a total value of $13,031,123.95. Following the transaction, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. This trade represents a 35.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 539,694 shares of company stock valued at $53,144,604. Insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.